The demand for sterile fill finish services has outpaced available capacity, leading to extended wait times and delayed clinical trials for sponsors. In response, Syngene is launching a state-of-art Sterile Fill Finish facility, building upon our years of sterile fill formulation development expertise to develop and manufacture:
Syngene’s Sterile Fill-Finish facility is custom-built to meet market demand for small-scale, sterile drug products having short development timelines. Our facility offers Drug substance and Drug product development and manufacturing for both large and small molecules.
Deciding on a partner for (DP) drug product development and clinical supply manufacturing for both small molecule and Biologics is one of the most critical decisions the sponsor makes on its program. Syngene has proven its ability to consistently provide:
Syngene offers more than just fill/finish of sterile injectables. Strong technical capabilities and broad parenteral resources help us align with your company’s clinical/commercial objectives and our shared goal of “putting science to work”
In this video, Syngene scientist Saurabh Sahu takes you through the capabilities and features of our integrated Sterile Fill-Finish facility for clinical supplies of Biologics and Small Molecules, as well as, products that are sensitive to light, heat and oxygen.